Exact Sciences Corporation Exact Sciences Corporation

Exact Sciences Corporation

EXAS

Hisse Senetlerindeki Sıralama #1156
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
Hisse Fiyatı
$104.91
Son senkronizasyon: 2026-03-23
Piyasa Değeri
$20.03B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
65.45%
Ülke
US
Ticaret Exact Sciences Corporation (EXAS)

Kategori

Healthcare
Exact Sciences Corporation (EXAS) için gelir
Dec 2025 itibarıyla gelir TTM: $3.25B
Exact Sciences Corporation şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $3.25B'dir. 2024 yılında şirketin geliri $2.76B önceki yıla göre artış 2023 yılındaki $2.50B gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Exact Sciences Corporation için 2000 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
2026 (TTM) $3.25B 0.00%
2025 $3.25B 17.69%
2024 $2.76B 10.37%
2023 $2.50B 19.93%
2022 $2.08B 17.95%
2021 $1.77B 18.49%
2020 $1.49B 70.19%
2019 $876.29M 92.82%
2018 $454.46M 70.86%
2017 $265.99M 167.66%
2016 $99.38M 151.99%
2015 $39.44M 2,093.38%
2014 $1.80M -56.61%
2013 $4.14M 0.00%
2012 $4.14M -0.46%
2011 $4.16M -22.10%
2010 $5.34M 12.32%
2009 $4.76M -648.79%
2008 $-867.00K -129.54%
2007 $2.94M -38.21%
2006 $4.75M 11.76%
2005 $4.25M -13.88%
2004 $4.94M 70.11%
2003 $2.90M 223.41%
2002 $897.00K 1,663.32%
2001 $50.87K 0.00%
2000 0.00 0.00%
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
$46.34B 1,327.04%
US
$25.11B 673.24%
US
$2.71B -16.63%
US
- -
CN
$7.37B 127.04%
US